Literature DB >> 12591639

Concordant pre- and postsynaptic deficits of dopaminergic neurotransmission in neurologic Wilson disease.

Henryk Barthel1, Wieland Hermann, Regine Kluge, Swen Hesse, David R Collingridge, Armin Wagner, Osama Sabri.   

Abstract

BACKGROUND AND
PURPOSE: Although previous brain imaging studies of Wilson disease (WD) focused on the dopaminergic system, correlational data on the integrity of the pre- and postsynaptic compartments are lacking. The present study was initiated to intra-individually determine the integrity of these compartments in patients with WD.
METHODS: A total of 46 patients with WD and 10 matched control subjects underwent [(123)I]2beta-carbomethoxy-3beta-(4[(123)I]iodophenyl)tropane ([(123)I]beta-CIT) and [(123)I]iodobenzamide ([(123)I]IBZM) single photon emission CT (SPECT). For both radiotracers, specific striatal binding ratios (with the cerebellum as the reference region) were calculated after a standardized region-of-interest technique was applied. In addition, the severity of putative neurologic symptoms was evaluated by using a linear scoring system.
RESULTS: In patients without neurologic symptoms, striatal binding ratios of both radiotracers did not differ from those of the control group (13.8 +/- 3.1 vs 12.0 +/- 3.4 and 2.00 +/- 0.19 vs 1.90 +/- 0.27; n.s.). In symptomatic patients, however, striatal binding ratios for both [(123)I]beta-CIT and [(123)I]IBZM were significantly reduced (9.1 +/- 2.3 and 1.64 +/- 0.18; P <.001). In all patients with WD, the [(123)I]beta-CIT and [(123)I]IBZM binding ratios were significantly correlated (r = 0.65, P <.001), as were SPECT parameters and the severity of the neurologic symptoms (r = -0.60 and -0.62; P <.001).
CONCLUSION: These findings of a concordant bicompartmental dopaminergic deficit in neurologic WD provide in vivo evidence for assigning WD to the group of secondary Parkinsonian syndromes. These results could be relevant in therapeutic decision making in patients with this copper deposition disorder.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12591639      PMCID: PMC7974120     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  24 in total

1.  Magnetic resonance imaging and proton MR spectroscopy in Wilson's disease.

Authors:  A Alanen; M Komu; M Penttinen; R Leino
Journal:  Br J Radiol       Date:  1999-08       Impact factor: 3.039

2.  Dopamine D2 receptor binding is reduced in Wilson's disease: correlation of neurological deficits with striatal 123I-iodobenzamide binding.

Authors:  W Oder; T Brücke; H Kollegger; J Spatt; S Asenbaum; L Deecke
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

3.  Treatment of Wilson's disease with L-dopa after failure with penicillamine.

Authors:  A Barbeau; H Friesen
Journal:  Lancet       Date:  1970-05-30       Impact factor: 79.321

4.  Wilson's disease: modification by L-DOPA.

Authors:  H J Gelmers; J Troost; J Willemse
Journal:  Neuropadiatrie       Date:  1973-12

5.  Differential alteration of the nigrostriatal dopaminergic system in Wilson's disease investigated with [123I]ss-CIT and high-resolution SPET.

Authors:  H Barthel; D Sorger; H J Kühn; A Wagner; R Kluge; W Hermann
Journal:  Eur J Nucl Med       Date:  2001-11

Review 6.  Parkinsonism. Multiple system atrophy.

Authors:  G K Wenning; N P Quinn
Journal:  Baillieres Clin Neurol       Date:  1997-04

7.  Neurological impairment and recovery in Wilson's disease: evidence from PET and MRI.

Authors:  G Schlaug; H Hefter; V Engelbrecht; T Kuwert; S Arnold; G Stöcklin; R J Seitz
Journal:  J Neurol Sci       Date:  1996-03       Impact factor: 3.181

8.  The nigrostriatal dopaminergic pathway in Wilson's disease studied with positron emission tomography.

Authors:  B J Snow; M Bhatt; W R Martin; D Li; D B Calne
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-01       Impact factor: 10.154

9.  Neurological Wilson's disease studied with magnetic resonance imaging and with positron emission tomography using dopaminergic markers.

Authors:  K Westermark; J Tedroff; K A Thuomas; P Hartvig; B Långström; Y Andersson; K Hörnfeldt; S M Aquilonius
Journal:  Mov Disord       Date:  1995-09       Impact factor: 10.338

10.  SPECT imaging of dopamine D2 receptors with 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease.

Authors:  K Tatsch; J Schwarz; W H Oertel; C M Kirsch
Journal:  Nucl Med Commun       Date:  1991-08       Impact factor: 1.690

View more
  16 in total

Review 1.  Industrial toxicants and Parkinson's disease.

Authors:  W Michael Caudle; Thomas S Guillot; Carlos R Lazo; Gary W Miller
Journal:  Neurotoxicology       Date:  2012-01-30       Impact factor: 4.294

Review 2.  Classification and differential diagnosis of Wilson's disease.

Authors:  Wieland Hermann
Journal:  Ann Transl Med       Date:  2019-04

3.  Establishment of hepatic and neural differentiation platforms of Wilson's disease specific induced pluripotent stem cells.

Authors:  Fei Yi; Jing Qu; Mo Li; Keiichiro Suzuki; Na Young Kim; Guang-Hui Liu; Juan Carlos Izpisua Belmonte
Journal:  Protein Cell       Date:  2012-07-18       Impact factor: 14.870

4.  Brain MRI, Tc-99m HMPAO SPECT and F-18 FP-CIT PET/CT Findings in a Patient with Wilson Disease: A Case Report.

Authors:  Seungyoo Kim; In Uk Song; Yong An Chung; Eun Kyung Choi; Jin Kyoung Oh
Journal:  Nucl Med Mol Imaging       Date:  2014-08-05

Review 5.  Sleep Disorders in Wilson's Disease.

Authors:  Valérie Cochen De Cock; France Woimant; Aurélia Poujois
Journal:  Curr Neurol Neurosci Rep       Date:  2019-11-13       Impact factor: 5.081

6.  Profound midbrain atrophy in patients with Wilson's disease and neurological symptoms?

Authors:  K Strecker; J P Schneider; H Barthel; W Hermann; F Wegner; A Wagner; J Schwarz; O Sabri; C Zimmer
Journal:  J Neurol       Date:  2006-04-10       Impact factor: 4.849

7.  Enhanced Mn-SOD immunoreactivity in the dopaminergic neurons of long-evans cinnamon rats.

Authors:  Dong Woon Kim; Tae-Beom Ahn; Jong Min Kim; Gye Sun Jeon; Je Hoon Seo; Beom S Jeon; Sa Sun Cho
Journal:  Neurochem Res       Date:  2005-04       Impact factor: 3.996

8.  Fine motor skills disorders in the course of Wilson's disease.

Authors:  Peter Albrecht Günther; Hans-Juergen Kühn; Thomas Villmann; Wieland Hermann
Journal:  Ann Indian Acad Neurol       Date:  2009-01       Impact factor: 1.383

9.  Copper dopamine complex induces mitochondrial autophagy preceding caspase-independent apoptotic cell death.

Authors:  Irmgard Paris; Carolina Perez-Pastene; Eduardo Couve; Pablo Caviedes; Susan Ledoux; Juan Segura-Aguilar
Journal:  J Biol Chem       Date:  2009-03-05       Impact factor: 5.157

Review 10.  [Diagnostics of Wilson's disease].

Authors:  W Hermann; D Huster
Journal:  Nervenarzt       Date:  2018-02       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.